Aaron D. Levine
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Aaron D. Levine has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
Dmitry M. Kissin
Division of Reproductive Health, Centers for Disease Control and Prevention, Atlanta, Georgia
2 shared publications- Sheree L. Boulet
Emory University
2 shared publications Albert Cheng
George W. Woodruff School of Mechanical Engineering, Georgia Institute of Technology, Atlanta, GA 30332, USA; Petit Institute for Bioengineering & Bioscience, Georgia Institute of Technology, Atlanta, GA 30332, USA
1 shared publication- Brittany P. Dodson
School of Public Policy, Georgia Institute of Technology, Atlanta, GA, USA.
1 shared publication - Denise J. Jamieson
Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, GA
1 shared publication - Dylan P. Reichert
Jimmy and Rosalynn Carter School of Public Policy, Ivan Allen College of Liberal Arts, Georgia Institute of Technology, Atlanta, USA
1 shared publication
Latest Publications
- 3 March 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (5) , 1569-1570
The rise and fall of US federally funded human fetal tissue research
- 3 March 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (5) , 1569-1570
The rise and fall of US federally funded human fetal tissue research
- Open Access
- 23 July 2024
- Published by Oxford University Press (OUP) in Stem Cells Translational Medicine
- Vol. 13 (9) , 851-858
The evolution and ongoing challenge of unproven cell-based interventions
Unproven cell-based interventions (CBIs) emerged early in the 2000s as a particularly problematic form of unproven therapy and remain a vexing policy problem to this day. These unproven interventions can harm patients both physically and financially and can complicate the process of developing a rigorous evidence base to support the translation of novel stem cell or other cell therapies. In this concise review, we examine the emergence of unproven CBIs and the various policy approaches that have been pursued or proposed to address this problem. We review the evolution of this field over the last 2 decades and explore why these policy efforts have proven challenging. We conclude by highlighting potential directions that the field could evolve and urging continued attention to both current and future forms of unproven CBIs to minimize future risks to patients and the field and to promote the development of evidence-based cell therapies.
- 23 July 2024
- Published by Oxford University Press (OUP) in Stem Cells Translational Medicine
- Vol. 13 (9) , 851-858
Open AccessThe evolution and ongoing challenge of unproven cell-based interventions
Unproven cell-based interventions (CBIs) emerged early in the 2000s as a particularly problematic form of unproven therapy and remain a vexing policy problem to this day. These unproven interventions can harm patients both physically and financially and can complicate the process of developing a rigorous evidence base to support the translation of novel stem cell or other cell therapies. In this concise review, we examine the emergence of unproven CBIs and the various policy approaches that have been pursued or proposed to address this problem. We review the evolution of this field over the last 2 decades and explore why these policy efforts have proven challenging. We conclude by highlighting potential directions that the field could evolve and urging continued attention to both current and future forms of unproven CBIs to minimize future risks to patients and the field and to promote the development of evidence-based cell therapies.
- Open Access
- 20 September 2022
- Published by Frontiers Media SA in Frontiers in Bioengineering and Biotechnology
- Vol. 10, 949280
Navigating ethical challenges in the development and translation of biomaterials research
Biomaterials--from implanted iron teeth in the second century to intraocular lenses, artificial joints, and stents today--have long been used clinically. Today, biomaterials researchers and biomedical engineers are pushing beyond these inert synthetic alternatives and incorporating complex multifunctional materials to control biological interactions and direct physiological processes. These advances are leading to novel strategies for targeted drug delivery, drug screening, diagnostics and imaging, gene therapy, tissue regeneration, and cell transplantation. While the field has survived ethical transgressions in the past, the rapidly expanding scope of biomaterials science, combined with the accelerating clinical translation of this diverse field calls for urgent attention to the complex and challenging ethical dilemmas these advances pose. This perspective responds to this call, examining the intersection of research ethics -- the sets of rules, principles and norms guiding responsible scientific inquiry -- and ongoing advances in biomaterials. While acknowledging the inherent tensions between certain ethical norms and the pressures of the modern scientific and engineering enterprise, we argue that the biomaterials community needs to proactively address ethical issues in the field by, for example, updating or adding specificity to codes of ethics, modifying training programs to highlight the importance of ethical research practices, and partnering with funding agencies and journals to adopt policies prioritizing the ethical conduct of biomaterials research. Together these actions can strengthen and support biomaterials as its advances are increasingly commercialized and impacting the health care system.
- 20 September 2022
- Published by Frontiers Media SA in Frontiers in Bioengineering and Biotechnology
- Vol. 10, 949280
Open AccessNavigating ethical challenges in the development and translation of biomaterials research
Biomaterials--from implanted iron teeth in the second century to intraocular lenses, artificial joints, and stents today--have long been used clinically. Today, biomaterials researchers and biomedical engineers are pushing beyond these inert synthetic alternatives and incorporating complex multifunctional materials to control biological interactions and direct physiological processes. These advances are leading to novel strategies for targeted drug delivery, drug screening, diagnostics and imaging, gene therapy, tissue regeneration, and cell transplantation. While the field has survived ethical transgressions in the past, the rapidly expanding scope of biomaterials science, combined with the accelerating clinical translation of this diverse field calls for urgent attention to the complex and challenging ethical dilemmas these advances pose. This perspective responds to this call, examining the intersection of research ethics -- the sets of rules, principles and norms guiding responsible scientific inquiry -- and ongoing advances in biomaterials. While acknowledging the inherent tensions between certain ethical norms and the pressures of the modern scientific and engineering enterprise, we argue that the biomaterials community needs to proactively address ethical issues in the field by, for example, updating or adding specificity to codes of ethics, modifying training programs to highlight the importance of ethical research practices, and partnering with funding agencies and journals to adopt policies prioritizing the ethical conduct of biomaterials research. Together these actions can strengthen and support biomaterials as its advances are increasingly commercialized and impacting the health care system.
- 15 February 2022
- Published by Springer Nature in Nature Biotechnology
- Vol. 40 (2) , 275-278
Assessing workforce needs for the emerging CAR-T cell therapy industry
- 15 February 2022
- Published by Springer Nature in Nature Biotechnology
- Vol. 40 (2) , 275-278
Assessing workforce needs for the emerging CAR-T cell therapy industry
- 1 August 2019
- Published by Elsevier in The Lancet Oncology
- Vol. 20 (8) , 1062-1064
Medical crowdfunding to access CAR T-cell therapy
- 1 August 2019
- Published by Elsevier in The Lancet Oncology
- Vol. 20 (8) , 1062-1064
Medical crowdfunding to access CAR T-cell therapy
- 1 April 2018
- Published by Taylor & Francis in Regenerative Medicine
- Vol. 13 (3) , 309-320
State Performance in Pluripotent and Adult Stem Cell Research, 2009–2016
Aim: To examine how the geographic distribution of pluripotent and adult stem cell research publications within the USA differs from other areas of biomedical research. Materials & methods: Publication count data for pluripotent stem cell research, adult stem cell research and a comparison group representative of biomedical research more broadly were collected and analyzed for each US state from 2009 to 2016. Results: The distribution of pluripotent stem cell research differed from the other fields with overperformance in pluripotent stem cell research observed in California, as well as Wisconsin, Massachusetts, Maryland and Connecticut. Conclusion: Our analysis suggests that permissive state stem cell policy may be one of the several factors contributing to strong state performance in pluripotent stem cell research.
- 1 April 2018
- Published by Taylor & Francis in Regenerative Medicine
- Vol. 13 (3) , 309-320
State Performance in Pluripotent and Adult Stem Cell Research, 2009–2016
Aim: To examine how the geographic distribution of pluripotent and adult stem cell research publications within the USA differs from other areas of biomedical research. Materials & methods: Publication count data for pluripotent stem cell research, adult stem cell research and a comparison group representative of biomedical research more broadly were collected and analyzed for each US state from 2009 to 2016. Results: The distribution of pluripotent stem cell research differed from the other fields with overperformance in pluripotent stem cell research observed in California, as well as Wisconsin, Massachusetts, Maryland and Connecticut. Conclusion: Our analysis suggests that permissive state stem cell policy may be one of the several factors contributing to strong state performance in pluripotent stem cell research.
- 1 November 2017
- Published by Elsevier in Fertility and Sterility
- Vol. 108 (5) , 815-821
Assessing the use of assisted reproductive technology in the United States by non–United States residents
- 1 November 2017
- Published by Elsevier in Fertility and Sterility
- Vol. 108 (5) , 815-821
Assessing the use of assisted reproductive technology in the United States by non–United States residents
- Open Access
- 28 March 2017
- Published by American Medical Association (AMA) in JAMA
- Vol. 317 (12) , 1272-1273
Contribution of Assisted Reproductive Technology to Overall Births by Maternal Age in the United States, 2012-2014
Assisted reproductive technology (ART) contributes to 1.6% of births in the United States,1 and utilization varies across several dimensions, including patient age.2 Delayed childbearing and age-related fertility declines may be associated with increasing ART use. Also, success rates for patients using their own oocytes decline with increasing maternal age, leading to higher use of donated oocytes by older women.2 The proportion of ART births among US multiple births by maternal age has been reported3; however, to our knowledge, age-specific estimates of the contribution of ART to total US births have not been previously published.
- 28 March 2017
- Published by American Medical Association (AMA) in JAMA
- Vol. 317 (12) , 1272-1273
Open AccessContribution of Assisted Reproductive Technology to Overall Births by Maternal Age in the United States, 2012-2014
Assisted reproductive technology (ART) contributes to 1.6% of births in the United States,1 and utilization varies across several dimensions, including patient age.2 Delayed childbearing and age-related fertility declines may be associated with increasing ART use. Also, success rates for patients using their own oocytes decline with increasing maternal age, leading to higher use of donated oocytes by older women.2 The proportion of ART births among US multiple births by maternal age has been reported3; however, to our knowledge, age-specific estimates of the contribution of ART to total US births have not been previously published.
- 1 January 2016
- Published by Elsevier in Cytotherapy
- Vol. 18 (1) , 143-148
Part 6: The role of communication in better understanding unproven cellular therapies
- 1 January 2016
- Published by Elsevier in Cytotherapy
- Vol. 18 (1) , 143-148
Part 6: The role of communication in better understanding unproven cellular therapies
- 12 November 2015
- Published by Springer Nature in Science and Engineering Ethics
- Vol. 22 (6) , 1649-1667
Navigating Bioethical Waters: Two Pilot Projects in Problem-Based Learning for Future Bioscience and Biotechnology Professionals
We believe that the professional responsibility of bioscience and biotechnology professionals includes a social responsibility to contribute to the resolution of ethically fraught policy problems generated by their work. It follows that educators have a professional responsibility to prepare future professionals to discharge this responsibility. This essay discusses two pilot projects in ethics pedagogy focused on particularly challenging policy problems, which we call “fractious problems”. The projects aimed to advance future professionals’ acquisition of “fractious problem navigational” skills, a set of skills designed to enable broad and deep understanding of fractious problems and the design of good policy resolutions for them. A secondary objective was to enhance future professionals’ motivation to apply these skills to help their communities resolve these problems. The projects employed “problem based learning” courses to advance these learning objectives. A new assessment instrument, “Skills for Science/Engineering Ethics Test” (SkillSET), was designed and administered to measure the success of the courses in doing so. This essay first discusses the rationale for the pilot projects, and then describes the design of the pilot courses and presents the results of our assessment using SkillSET in the first pilot project and the revised SkillSET 2.0 in the second pilot project. The essay concludes with discussion of observations and results.
- 12 November 2015
- Published by Springer Nature in Science and Engineering Ethics
- Vol. 22 (6) , 1649-1667
Navigating Bioethical Waters: Two Pilot Projects in Problem-Based Learning for Future Bioscience and Biotechnology Professionals
We believe that the professional responsibility of bioscience and biotechnology professionals includes a social responsibility to contribute to the resolution of ethically fraught policy problems generated by their work. It follows that educators have a professional responsibility to prepare future professionals to discharge this responsibility. This essay discusses two pilot projects in ethics pedagogy focused on particularly challenging policy problems, which we call “fractious problems”. The projects aimed to advance future professionals’ acquisition of “fractious problem navigational” skills, a set of skills designed to enable broad and deep understanding of fractious problems and the design of good policy resolutions for them. A secondary objective was to enhance future professionals’ motivation to apply these skills to help their communities resolve these problems. The projects employed “problem based learning” courses to advance these learning objectives. A new assessment instrument, “Skills for Science/Engineering Ethics Test” (SkillSET), was designed and administered to measure the success of the courses in doing so. This essay first discusses the rationale for the pilot projects, and then describes the design of the pilot courses and presents the results of our assessment using SkillSET in the first pilot project and the revised SkillSET 2.0 in the second pilot project. The essay concludes with discussion of observations and results.